Ronald Blue Trust, Inc. Kymera Therapeutics, Inc. Transaction History
Ronald Blue Trust, Inc.
- $7.98 Billion
- Q3 2024
A detailed history of Ronald Blue Trust, Inc. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 361 shares of KYMR stock, worth $16,587. This represents 0.0% of its overall portfolio holdings.
Number of Shares
361
Previous 278
29.86%
Holding current value
$16,587
Previous $8,000
112.5%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding KYMR
# of Institutions
181Shares Held
64.4MCall Options Held
45.1KPut Options Held
32.6K-
Price T Rowe Associates Inc Baltimore, MD6.65MShares$305 Million0.04% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$276 Million3.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$237 Million7.77% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$225 Million28.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.75MShares$218 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.51B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...